Experimental
GHRP-6
The prediction game
Call it: rising or fading?
Where does GHRP-6 stand 12 months from now? Lock your call with a confidence level. When the window closes, the Brier rule scores your calibration: right and confident earns the most, wrong and confident costs the most. Points and a leaderboard spot are the whole prize. No stakes, no money.
One call per intervention. It locks the moment you submit: no edits, no cancels. It resolves when the 12-month window closes.
The Crowd’s Call
Rising or fading over the next 12 months? Lock your call and find out if you saw it coming.
Community Signal
No weigh-ins yet. Be the first and set the early signal.
Evidence
Evidence grade: C (mixed evidence)
Graded from the strength of the published research, independent of any verdict on this page.
Evidence Anchor
BioHarmony 5.1/10
GHRP-6 sits in caution because it pairs a real, fast, historically important mechanism with an empty human outcomes file and the heaviest side-effect load of its group. It is one of the original growth-hormone-releasing peptides and genuinely pivotal to the science, but for the growth-hormone-optimization goal it is the weakest practical choice. The growth-hormone rise is real, per Bowers 1990, but no trial shows it produces fat loss or muscle, and the strong appetite, separate from growth hormone, per Locke 1995, actively fights a cutting goal. If you specifically want the hunger for a hard bulk, it has a niche. For almost everyone else, a selective option does the same job with fewer downsides. ✅ Best for: Experienced users running a hard mass or bulking phase who actively want the appetite boost to eat in a surplus, the one place the hunger is a feature instead of a bug. People curious about the oldest growth-hormone-releasing peptide and its place in the discovery of ghrelin. Users who already stack a GHRH peptide and want to compare the older option directly. Anyone who can source verified material with a certificate of analysis and will monitor IGF-1 and glucose. People who understand they are running an unproven, grey-market research chemical and accept that. ❌ Avoid if: You have a fat-loss goal, because the strong appetite works directly against eating less. You have active or hormone-sensitive cancer, since growth-hormone and IGF-1 signaling can promote proliferation. You are pregnant or breastfeeding, with no safety data. You have diabetes or poor glucose control, because growth hormone opposes insulin, per White 2009. You compete in tested sport, since growth-hormone-releasing peptides are banned at all times under WADA category S2. You want the cleanest option, in which case ipamorelin avoids most of the appetite and cortisol effect. You cannot verify source quality, since research-chemical contamination may exceed the intrinsic pharmacological risk.
Read the full BioHarmony report
My score and my verdict: one signal of three, never the whole answer.
Momentum
Signals begin with Edition 2
Direction needs two weekly snapshots to compare, so the arrows stay off until the next edition. Attention tracking is already running.
Momentum = how fast attention is rising across search, Reddit, PubMed, podcasts, and curated industry newsletters this week; it can flag an item as Overhyped/Fading, but it never overrides the evidence behind Proven. How momentum works.
- Ring
- Experimental
- Trend
- Begins with Edition 2
- Momentum
- 3.6%
- BioHarmony Score
- 5.1/10
- Last Updated
- Jul 2, 2026
Sources
- BioHarmony score
- Search trend delta
- Reddit velocity
- PubMed publication count
- Podcast mention frequency
- Curated newsletter mentions
The score anchors the ring; the other five drive momentum, which can nudge the ring by one step at most. How placement works.
Weigh In
Your input feeds the community signal shown beside my verdict. It informs the board and it never sets the score by itself. How community input works.
New voice here? We send a one-tap verification link so every entry comes from a real person. Signed-in members skip this.